Drug-eluting stenting of saphenous vein graft versus native coronary artery supplying the same myocardial perfusion territory: A pilot retrospective 3-year follow-up

Journal of Invasive Cardiology

Volumn 24, Issue 10, 2012, Pages 516-520

  Ho, Paul C ^a   Lee, Arthur C ^a   Fortuna, Richard ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

degenerative saphenous vein graft

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; EVEROLIMUS; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG ELUTING STENT; EXERCISE TEST; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE PERFUSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; REVASCULARIZATION; SAPHENOUS VEIN GRAFT; SMOKING; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DEATH, SUDDEN, CARDIAC; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PILOT PROJECTS; RETROSPECTIVE STUDIES; SAPHENOUS VEIN; SIROLIMUS; TREATMENT OUTCOME;

EID: 84867768357     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Guthaner DF, Robert EW, Alderman EL, Wexler L. Long-term serial angiographic studies after coronary artery bypass surgery. Circulation. 1979;60(2):250-259.
2. Krone RJ, Shaw RE, Klein LW, et al; for the ACC-National Cardiovascular Data Registry. Evaluation of the American College of Cardiology/American Heart Association and the Society for Coronary Angiography and Interventions lesion classification system in the current "stent era" of coronary interventions (from the ACC-National Cardiovascular Data Registry). Am J Cardiol. 2003;92(4):389-394.
3. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents. J Am Coll Cardiol. 2005;45(7):989-994.
4. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323.
5. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, Paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350(3):221-231.
6. Varghese I, Samuel J, Banerjee S, Brilakis ES. Comparison of percutaneous coronary intervention in native coronary arteries vs bypass grafts in patients with prior coronary artery bypass graft surgery. Cardiovasc Revasc Med. 2009;10(2):103-109.
7. Garcia-Tejada J, Velazquez M, Hernandez F, et al. Percutaneous revascularization of grafts versus native coronary arteries in postcoronary artery bypass graft patients. Angiology. 2009;60(1):60-66.
8. D'Ascenzo F, Gonella A, Longo G, et al. Short and long-term outcomes of percutaneous revascularization in patients with prior coronary artery bypass graft. Minerva Cardioangiologica. 2010;58(3):291-299.
9. Meliga E, Garcia-Garcia HM, Kukreja N, et al. Chronic total occlusion treatment in post-CABG patients: saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era. Catheter Cardiovasc Interv. 2007;70(1):21-25.
10. Grantham JA, Marso SP, Spertus J, House J, Holmes DR Jr, Rutherford BD. Chronic total occlusion angioplasty in the United States. JACC Cardiovasc Interv. 2009;2(6):479-486.
11. Thompson CA, Jayne JE, Robb JF, et al. Retrograde techniques and the impact of operator volume on percutaneous intervention for coronary chronic total occlusions an early US experience. JACC Cardiovasc Interv. 2009;2(9):834-842.
12. Brodie BR, VerSteeg DS, Brodie MM, et al. Poor long-term patient and graft survival after primary percutaneous coronary intervention for acute myocardial infarction due to saphenous vein graft occlusion. Catheter Cardiovasc Interv. 2005;65(4):504-509.
13. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002;106(24):3063-3067.
14. Minutello RM, Bhagan S, Sharma A, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol. 2007;20(6):458-465.
15. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv. 2005;66(4):507-511.
16. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48(12):2423-2431.
17. Mehilli J, Pache J, Abdel-Wahab M, et al; for the "Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts?" (ISAR-CABG) investigators. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomized controlled superiority trial. Lancet. 2011;378(9796):1071-1078.
18. Vermeersch P, Agostoni P, Verheye S, et al; DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis in Saphenous vein grafts with Cypher stent) investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol. 2007;50(3):261-267.
19. Bansal D, Muppidi R, Singla S, et al. Percutaneous intervention on the saphenous vein bypass grafts-long-term outcomes. Catheter Cardiovasc Interv. 2008;71(1):58-61.
20. Harjai KJ, Sattur S, Orshaw P, Boura J. Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents following successful PCI in non-ST elevation myocardial infarction: findings from the Guthrie Health Off-Label StenT (GHOST) registry. J Interv Cardiol. 2012;25(1):28-36.
21. Puymirat E, Mangiacapra F, Peace A, et al. Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare metal stenting. Am Heart J. 2011;162(5):907-913.
22. Ramanath VS, Brown JR, Malenka DJ, et al; Dartmouth Dynamic Registry Investigators. Outcomes of diabetics receiving bare-metal stents versus drug-eluting stents. Catheter Cardiovasc Interv. 2010;76(4):473-481.
23. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guidelines for percutaneous coronary intervention. Circulation. 2011;124:E574-E651.
24. Mehta SK, Frutkin AD, Milford-Beland S, et al. American College of Cardiology-National Cardiovascular Data Registry. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol. 2007;100(7):1114-1118.
25. Matar FA, Smith K, Rossi P, et al. Limitations of embolic protection in saphenous vein graft intervention: insights from 202 consecutive patients. J Interv Cardiol. 2009;22(3):240-246.
26. Badhey N, Lichtenwalter C, de Lemos JA, et al. Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv. 2010;76(2):263-269.
27. Assali AR, Sdringola S, Moustapha A, et al. Percutaneous intervention in saphenous venous grafts: in-stent restenosis lesions are safer than de novo lesions. J Invasive Cardiol. 2001;13(6):446-450.
28. Cicek D, Doven O, Pekdemir H, et al. Procedural results and distal embolization after saphenous vein graft stenting and angioplasty for in-stent restenosis of grafts. Jpn Heart J. 2004;45(4):561-571.
29. Sano K, Mintz GS, Carlier SG, et al. Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts. Am J Cardiol. 2006;97(10):1463-1466.
30. Hong YJ, Jeong MH, Ahn Y, et al. Impact of lesion location on intravascular ultrasound findings and short-term and five-year long-term clinical outcome after percutaneous coronary intervention for saphenous vein graft lesions. Int J Cardiol. 2011 Dec 20 (Epub ahead of print).
31. Lavi S, Ivanov J, Appleby CE, et al. Selective use of embolic protection devices during saphenous vein grafts interventions: a single-center experience. Catheter Cardiovasc Interv. 2010;75(7):1037-1044.